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Abstract
Firstly, comparisons have been made of the secretion of human growth hormone (HGH) that
was induced by insulin, lysine vasopressin and pyrogen injections in order to study whether these
substances can be utilized as a rapid test of HGH secretion. In insulin test, a fall of the fasting blood
glucose level by 28.6% or more seemed to be sufficient to provoke adequate HGH elevation, and
9.4 ng/ml or higher HGH increment was recognized as being normal, because lysine vasopressin
and pyrogen produce varying degrees of side-effects and are less specific and unpredictable in
the release of HGH. Secondly, the pharmacologic effects and mechanism of action of exogenous
glucagon upon the HGH secretion were studied. In normal subjects after one mg sc glucagon,
there was a mean peak blood glucose level of 142. 4±3.l mg/lOO ml at 30 min, HGH levels
reached a mean peak level of 22. 6±4. 8 ng/ml at 150 min, and no false negative response was
noted. In patients with hypopituitarism, there was no positive response in plasma HGH levels after
the sc glucagon. The present study revealed that the rise and subsequent fall of blood glucose are
not the sole mechanism responsible for the effct of glucagon on HGH secretion, and that the HGH
secretion in response to the sc glucagon was not triggered by cathecholamine via the stimulation
of the adrenal medulla.
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Abstract: Firstly, comparisons have been made of the secretion of
human growth hormone (HGH) that was induced by insulin, lysine
vasopressin and pyrogen injections in order to study whether these
substances can be utilized as a rapid test of HGH secretion. In
insulin test, a fall of the fasting blood glucose level by 28.6% or
more seemed to be sufficient to provoke adequate HGH elevation,
and 9.4 ng/ml or higher HGH increment was recognized as being
normal, because lysine vasopressin and pyrogen produce varying
degrees of side-effects and are less specific and unpredictable in
the release of HGH. Secondly, the pharmacologic effects and me-
chanism of action of exogenous glucagon upon the HGH secretion
were studied. In normal subjects after one mg sc glucagon, there
was a mean peak blood glucose level of 142. 4±3.l mg/lOO ml at 30
min, HGH levels reached a mean peak level of 22. 6±4. 8 ng/ml at
150 min, and no false negative response was noted. In patients with
hypopituitarism, there was no positive response in plasma HGH levels
after the sc glucagon. The present study revealed that the rise and
subsequent fall of blood glucose are not the sole mechanism responsible
for the effct of glucagon on HGH secretion, and that the HGH secre-
tion in response to the sc glucagon was not triggered by cathechola-
mine via the stimulation of the adrenal medulla.
The secretion of human growth hormone (HGH) has been extensively
studied in man in recent years. The administration of many different sub-
stances has been used to assess the HGH reserve since the demonstration of
insulin-induced hypoglycemia as a stimulus of HGH secretion (1). As insulin,
lysine vasopressin and pyrogen can be used for the simple test of the hypo-
thalamo-pituitary-adrenocortical axis for the secretion of cortisol, it seems
worthwhile to study whether these substances Can also be utilized as the rapid
test of the hypothalamo-pituitary axis for the secretion of HGH. The first
aim of this study is to compare the effects of insulin, lysine vasopressin and
pyrogen injection on the release of HGH, and to define a normal range of
response, so that similar tests performed in patients with a variety of endocrine
and other disorders can be interpreted.
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Variable results have appeared in literatures concerning the capability of
glucagon to provoke the release of HGH. Plasma HGH levels, although once
considered unaffected by glucagon (1, 2), have been found to increase follow-
ing the subcutaneous injection of glucagon (3-5). At prerent, HGH secretion
in response to subcutaneous injection of glucagon is generally accepted. How-
ever, the mechanism of glucagon action on HGH secretion is yet unclarified,
and only a few reports are available on the application of glucagon test to
patients with various diseases. As the second aim, this study was designed to
ascertain the pharmacologic effects and mechanism of action of exogenous
glucagon upon the HGH secretion.
TABLE 1 PLASMA HGH AND BLOOD GLUCOSE CONCENTRATIONS AFTER
No. of Plasma HGH (ng/ml)
Diagnosis 0 30 60 90 maximalpatients
min min min min maximum increment
normal 40 Maen 2. 7 10.1 29.1 17.8 29.6 27.0
subjects SEM 0.3 1.7 2.0 1.5 1.9 1.9
normal 19 Mean 3.4 10.7 31. 6 20.9 32.2 29.1
males SEM 0.4 2.3 3.1 2.5 3.0 3.0
normal 21 Mean 2.2 9.5 26.9 14.7 27.3 23.3
females SEM 0.4 2.3 2.4 1.4 2.4 2.4
acromegaly 6 Mean 82.5 104.0 110.2 99.3 115.3 32.8
SEM 14.9 19.8 20.6 20. 7 19.3 15.6
panhypopi tuitarism
Sheehan's 4 Mean 1.4 2.1 4.2 3.3 4.3 3.0
syndrome SEM 0.2 0.8 2.4 1.8 2.3 2.2
postoperative 12 Mean 1.4 1.5 1.3 1.4 1.6 0.3
hypothalamopituitary tumor SEM 0.2 0.2 0.1 1.0 0.2 0.1
pituitary 10 Mean 1.1 1.2 1.0 0.9 1.4 0.4
dwarfism SEM 0.2 0.3 0.2 0.2 0.2 0.1
primordial 5 Mean 3.9 19.3 23.3 13.7 24. 7 20.9
dwarfism SEM 1.3 3.4 4.6 2.9 3.9 3.8
hypogonadotropic 8 Mean 2.3 9.8 11. 7 8.8 13.9 11. 7
hypogonadism SEM 0.3 2.8 1.6 2.4 2.6 2.4
idiopathic diabetes 10 Mean 1.0 4.6 8.8 6.2 9.5 8.5
insipidus SEM 0.3 2.2 3.2 2.4 3.1 3.3
hyperthyroidism 9 Mean 4. 7 7.1 14.1 10.4 15.8 II. 9
SEM 2.3 1.0 2.9 2.4 3.0 3.6
hypothyroidism 5 Mean 2.3 3.3 3.5 3.2 4.1 2.4
SEM 0.8 0.8 1.3 0.9 1.3 1.1
Cushing's 7 Mean 0.8 3.8 4.0 1.1 4.4 3.6
syndrome SEM 0.2 2.1 2.0 0.1 2.1 2.0
diabetes mellitus 15 Mean 3.2 9.1 11. 9 8.4 15. 7 12.5
SEM 0.5 3.1 2.0 1.6 2.6 2.6
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MATERIALS AND METHODS
All tests were begun at 9 AM after an overnight fast. The subjects were
kept in the horizontal position for 30 min before withdrawal of the first blood
sample to minimize the effect of previous exercise. Serial blood specimens
were sampled through an indwelling venous catheter or venipuncture using
heparinized syringes. The plasmas were immediately separated and frozen
until HGH was assayed.
1. Insulin test
A total of 131 tests were performed on 40 normal subjects and 91 patients
whose clinical diagnoses are summarized in Table 1.
IV ADMINISTRATION OF REGULAR INSULIN (0. 1U/kg).
Blood glucose (mg/lOOml) ~ decrement of blood
0 30 60 90 minimum glucose
min min min min
103.6 57.1 79.6 89.9 55.5 47.0~
2.5 2.3 2.3 2.6 2.2 1.8~
103.9 57.4 83.4 90.1 57.1 44.9~
2.4 2.6 2.3 2.2 2.5 2.5~
103.2 56.8 76.1 89.8 54.0 48.9~
4.2 3.8 3.7 4. 7 3.5 2.4~
168.0 141.3 150.0 140.0 121. 3 29.4~
49.0 55.0 44.1 31. 2 38.7 1.8~
94.8 52.0 70.0 80. 7 45.5 53.9~
14.5 18. 7 9.1 9.5 13.2 6.9~
96.9 53.1 75.2 77.3 53.1 46.4~
4. 7 2.9 6.1 5.2 2.9 1. 7~
88. 1 49.7 73.6 74. 7 49. 7 43.1~
4.2 3.2 4. 7 5.2 3.2 3.6~
114.8 54.0 76.8 84.0 54.0 5O.1~
14.1 3.3 8.2 10.0 3.3 5.3~
103.8 66.5 87.8 93.3 66.5 36.5~
4.2 6.3 5.9 5.9 6.3 4.5~
109.6 56.3 85.9 109.2 50.1 48. 7~
4.0 5. 7 4. 7 14.1 7.7 4.8~
102.0 61. 6 83.8 94.4 61.6 39. 7~
5.4 5.4 5.8 5.3 5.4 3.9~
92.0 50.4 70.4 69.5 49.6 46.0~
4.4 4.2 7.9 8.3 3.9 3.4~
113.5 78. 7 87.2 95.3 66.3 37. 7~
18.5 17.2 7.1 3.8 6.8 6.6%
185.7 132.1 123.1 122.6 112.4 41.2~
17.4 17.8 14.7 13.1 16.3 4.5~
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After a basal blood sample was drawn, the 0.1 Ujkg BW of regular in-
sulin was injected intravenously (iv). Blood samples were then taken at 30 min
intervals for 90 min. Blood glucose and plasma HGH levels were measured
in these specimens.
2. Lysine vasopressin (LVP) test
A total of 33 tests were carried out as controls in 33 volunteers and hospita-
lized people who had no clinical or biochemical evidence of endocrine, hepatic,
or renal dysfunction. The four units of synthetic lysine vasopressin (Sandoz)
were injected iv. Blood samples were drawn at 0, 15, 30 and 60 min.
In order to compare the effect of LVP and insulin on the release of HGH,
27 subjects out of them also received the insulin test.
3. Pyrogen test
As controls, 16 tests were performed in 16 volunteers and hospitalized in.
dividuals who had no clinical or biochemical evidence of endocrine, hepatic, or
renal dysfunction. After a basal blood sample was drawn, the 0.005 ,lLg/kg
BW of "pyrogen E" (Organon) was injected iv. Additional blood samples were
taken at 120 and 180 min after injection of pyrogen.
In order to compare the effect of pyrogen and insulin on the release of
HGH, 13 subjects out of them had also undergone the insulin test.
4. Glucagon test
The subjects were 8 normal males, 6 normal females, 6 patients with hypo.
pituitarism, 6 with diabetes mellitus, one adrenalectomized bilaterally due to
Cushing's syndrome, and two with Addison's disease.
After a basal blood sample was drawn, one mg of crystalline glucagon
(Novo Industri A/S, Copenhagen, Denmark) was injected subcutaneously (sc).
Additional blood samples were drawn at 30, 60, 90, 120, 150 and 180 min after
injection of glucagon. Blood glucose and plasma HGH levels were measured
in these specimens.
In order to investigate the specificity and the effect of the dose of glucagon
on the secretion of HGH, subcutaneous injection of physiological saline and
one mg and two mg glucagon were repeatedly carried out in one normal male
subject.
In four normal males, oral administration of two, two and four mg dexa.
methasone was carried out at 1 PM, 7 PM and 11 PM respectively on the pre·
vious day, in order to study the influence of dexamethasone on the glucagon.
induced HGH secretion.
5. Assqy methods
Blood glucose was determined by an auto.analyzer using ferricyanide pro-
cedure (6), and plasma HGH by radioimmunoassay using a double antibody
separation procedure.
RESULTS
1. I nsulin test
Table I shows the levels of BGH and blood glucose obtained before and
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after insulin hypoglycemia in all subjects.
Normal subjects showed a mean fall in blood glucose after insulin from
the fasting level of 103. 6±2. 5 mg/lOO ml to 57. 1±2. 3 mg/lOO ml at 30 min,
followed by a return to preinsulin levels. The mean per cent decrement in
blood glucose was 47.0% of the fasting level. In normal subjects, maximum
HGH levels following insulin hypoglycemia ranged from 11. 3 to 60. 0 ng/ml
with a maximum mean of 29.6 ng/ml. Although the highest levels usually
occurred at 60 min, two and three out of 40 normal subjects peaked at 30 and
90 min, respectively. Although no significant correlation (r= +0. 097, P>
0.5) was obtained between the absolute minimal blood glucose levels and
the HGH increments (Fig. 1), significant correlations (r = +O. 631, P<O. 001,
y = O. 6x - 1. 2) were observed between per cent decrement in blood glucose
and the HGH increments (Fig. 2). This indicates that the HGH response may
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Fig. 1. Comparison of minimal blood
glucose levels and HGH increments fol-
lowing insulin in 40 normal subjects. Each
dashed line represents two SD below or
above the logarithmic mean.
Fig. 2. Correlation between per cent
decrements in blood glucose and the HGH
increments following insulin in 40 normal
subjects. Each dashed line represents two
SD below the logarithmic mean.
be related to the per cent blood glucose decrement rather than to the absolute
minimal blood glucose levels. Because of the skew distribution, the data
were analyzed after logarithmic transformation for definition of the normal
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range. The 95% confidence limits were considered to be the logarithmic
mean ± 2 SD. By this analysis, the mean per cent blood glucose decrement
of 40 normal subjects following insulin-induced hypoglycemia was 45.8%,
with 95% confidence limits of 28.6 to 73.5%, and the mean HGH increment
was 24.4 ng/m1, with 95% confidence limits 9.4 to 62. 7 ng/ml. Namely,
the fall of the fasting blood glucose level by 28.6% or more seemed to be
sufficient to provoke an adequate HGH elevation, and 9. 4 ng/m1 or higherHGH increment was recognized as being normal. This criterion should be
applied to LVP test and pyrogen test.
Six patients with acromegaly had fasting HGH levels ranging from 45. 0
to 160.0 ng/ml. Although HGH increase was noted in three out of six sub-jects following insulin, no HGH increase was noted in three subjects.
The panhypopituitarism group had no change in plasma HGH levelsfollowing insulin hypoglycemia. The blood glucose response to insulin ad-
ministration was similar to that seen in the normal subjects.
Although five patients with primordial dwarfism had a normal increasein HGH, 10 patients with pituitary dwarfism failed to show any change in
HGH with insulin-induced hypoglycemia.
In 8 patients with hypogonadotropic hypogonadism, the mean HGH in-
crement following insulin was in the normal range but it was significantlylower (P<O. 01) than that in normal subjects.
Despite a very similar fall in blood glucose following insulin in the 10patients with idiopathic diabetes insipidus as shown in Table 1, the corres-ponding change in plasma HGH levels was from a basal mean value of 1. 0
± O. 3 ng/ml to only 8. 8 ± 3. 2 ng/ml at 60 min.
In 9 patients with hyperthyroidism, the mean HGH increment was in
the normal range but it was significantly lower (P<O. 01) than that in normal
subjects. On the other hand, the hypothyroidism had a small increase in
HGH levels following insulin.
In 7 patients with Cushing's syndrome, a markedly impoverished HGH
response to insulin was seen.
The mean HGH increment of diabetics following insulin hypoglycemia
was in the normal range but it was significantly lower (P<O. 05) than that in
normal subjects.
Transient hypoglycemia symptoms usually occurred about 40 min after
administration of insulin. These consisted of drowsiness, excessive perspi-
ration, and hunger.
2. Lysine vasopressin (LVP) test
The iv injection of LVP induced 9.4 ng/ml or higher HGH increment in
6
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only 9 of 33 control subjects tested (Fig. 3).
A comparison of HGH increments obtained following insulin and LVP
is shown in Fig. 4. Despite 20 out of 27 control subjects tested respond to
insulin test, only six of 27 subjects respond to LVP test, There is no signifi-
cant correlation (r= -0.131, p>o. 5) between HGH increments obtained from
insulin test and those from LVP test.
60
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Fig. 3. Plasma HGH response to iv
administration of four U LVP in 33 con-
trol subjects.
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Fig. 4. Comparison of the HGH in-
crements following insulin and LVP in
27 control subjects. The dashed line re-
presents the normal threshold (9.4ng/ml),
which is adopted in the present paper.
Most of subjects tested complained of the abdominal colic at 2 to 5 min
after iv administration of LVP.
3. Pyrogen test
Following the iv injection of pyrogen, the HGH increments were beyond
9.4 ng/ml in only 5 of 16 control subjects tested (Fig. 5).
A comparison of HGH increments obtained following insulin and pyro-
gen is shown Fig. 6. There is no significant correlation (r= -0.038, P>0.9)
between HGH increments obtained from insulin test and those from pyrogen
test,
Furthermore, the discomfort, such as pyretic response to the patients
7
Ogawa: Stimulation tests of human growth hormone secretion by insulin
Produced by The Berkeley Electronic Press, 1974
188 N. OGAWA
50
N::13
r::-0.038
P>0.9
40 •
Fig. 5. Plasma HGH response to iv
administration of pyrogen (0.OO5pg/kg) in
16 control subjects.
E
0.
.5- 30
.5:
C :;Ul
..
.5:E
~
u i 20.5:
'E
:I:
t.:>
:I:
I
10 •• •• r - - - - • - - - - • _ - - •• _. __
.
: .
. ,
,
10 20 30
HGH increment (ng/ml)
after pyrogen
Fig. 6. Comparison of the HGH in-
crements following insulin and pyrogen
in 13 control subjects. The dashed line
represents the normal threshold (9.4
ng/ml), which is adopted in the present
paper.
receiving pyrogen, argues against its use in diagnosis.
4. Glucagon test
Table 2 summarizes the HGH values after repeated sc administration of
physiological saline and one mg or two mg glucagon in one normal male
subject. HGH values failed to change significan.tly in response to physio-
logical saline. Responses of HGH were similar between administrations of
TABLE 2 REPRODUCIBILITY OF PLASMA HGH RESPONSE TO SC GLUCAGON
ON 5 OCCASIONS IN A NORMAL MALE SUBJECT.
----,._._----~~--- .
plasm HGH (ng/ml) blood glucose (mg/IOOml)
-
-_.- _..._.._~-----~----- _.._-----
glucagon 0 30 60 90 120 150 180 0 30 60 90 120 150 180
min min min min min min min min min min min min min min
---------------
I mg 0.9 1.2 1.0 1.0 4.9 20.0 17.2 90 150 122 98 86 80 92
I mg 1.3 2.9 1.8 2.2 1.2 22.5 19.9 104 148 112 94 86 98 104
I mg O. 7 1.5 1.7 1.2 0.8 38.3 40.0 104 152 138 100 70 80 70
2mg 1.0 1.0 0.8 1.1 3.9 22.0 20.0 80 148 126 106 84 80 94
2mg 2.1 2.0 0.9 0.6 1.7 3.2 23.8 94 156 120 100 88 88 92
saline only 1.0 4.4 5.0 3.9 2. 7 1.8 2. 7
8
Acta Medica Okayama, Vol. 28 [1974], Iss. 3, Art. 5
http://escholarship.lib.okayama-u.ac.jp/amo/vol28/iss3/5
Stimulators of Human Growth Hormone Secretion 189
one mg and two mg glucagon, indicating that the sc injection of one mg
glucagon is sufficient for the stimulation test of HGH secretion.
Table 3 shows the mean values of plasma HGH and of blood glucose at
various times after glucagon sc injection, including standard errors of the
means. In normal subjects after one mg sc injection of glncagon, there was
an increase in blood glucose levels from a mean baseline level of 95. 9 ± 1. 8
mg/lOOml (5E) to a mean peak level of 142. 4±3. lmg/lOOml (5E) at 30 min,
and then blood glucose levels fell slightly below the baseline levels at 90-180
min. HGH levels reached a mean peak level of 22. 6±4. 8 ng/ml (5E) at
150 min and remained elevated at 180 min, and they were significantly higher
(P<O. 001) than the mean baseline level of 2.5 ± 0.5 ng/ml (5E). The range
of maximal HGH levels after glucagon was 13. 2-60. 5 ng/ml. In patients
with hypopituitarism, blood glucose levels reached a mean peak level of
129. 4±9. 6 mg/lOO ml (5E) at 30 min without significant difference (0. l>P
>0.05) from normal subjects, but there was no positive response in plasma
HGH levels and plasma HGH concentrations at each interval did not differ
significantly from those at 0 time.
In patients with diabetes mellitus, blood glucose levels reached a mean
peak level of 223± 14.2 mg/lOO ml at 60 min, followed by a slow decline
and returning to the previous level at 180 min. While the blood glucose con-
centrations at each interval in patients with diabetes mellitus was much
higher (P<O. 001) than in the controls, the peak values of HGH (18. 1± 3. 1
ng/ml, at 150 min) were the same as those of normal controls (0. 4>P>O. 3).
In four normal male subjects, 8 mg of dexamethasone were orally admi-
nistered on the day before the glucagon test. Blood glucose levels at each
interval were significantly higher (at 0-120 min: P<O. 001; at 150 min:
0.01 <P<O. 02; at 180 min: not significant) than in normal male subjects,
and high blood glucose levels persisted. However, the HGH secretion showed
a pattern similar to that in normal male subjects, without significant differ-
ence. On the other hand, plasma cortisol levels were completely suppressed
in these cases.
In order to remove the hyperglycemic response alone, 0.09 U/kg regular
insulin was injected in a normal male subject along with sc injection of
glucagon. As the result, there was no change in blood glucose levels but
the HGH secretion was present (Fig. 7). In a patient adrenalectomized bila-
terally due to Cushing's syndrome who was under replacement therapy with
37.5 mg/day cortisone acetate and in two patients with Addison's disease,
glucagon test gave the same HGH secretion as in normal subjects (Table 4).
Occasionally, some patients complained of an increased sensation of
hunger, or of slight nausea at 120 min after injection of glucagon.
9
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TABLE 3 PLASMA HGH AND BLOOD GLUCOSE
No. of Plasma HGH
Diagnosis 0 30 60 90 120
subjects
min min min min min
normal subjects 14 Mean 2.5 2.3 2.4 5.9 11. 9
SEM 0.5 0.4 0.5 1.8 3.0
normal males 8 Mean 1.9 1.7 1.9 3.4 II. 5
SEM 0.4 0.3 0.4 2.1 4.8
normal females 6 Mean 3.9 3. I 3. I 9.2 12.4
SEM O. 7 0.8 1.1 2.9 3.8
panhypopi tu tarism 6 Mean 1.1 1.3 1.2 1.4 1.4
SEM 0.2 0.2 0.3 0.3 0.2
diabetes mellitus 6 Mean 2.0 2. 7 2.9 5.6 14.6
SEM 1.0 1.0 0.9 1.4 3.8
dexamethasone premedi- 4 Mean 2.8 3. I 9.0 12.3 20.9
cated normal males SEM 1.1 1.3 2.5 3.2 7.7
TABLE 4 PLASMA HGH AND BLOOD GLUCOSE RERPONSE TO SC INJECTiON OF GLUCAGON IN
Plasma HGH
Initials Age Sex Diagnosis 0 30 60 90 120
min min min min min
S.K. 33 M adrenalectomized bilaterlly 1.0 4.0 0.1 4.2 14.8
(Cushing's syndrome)
a.M. 55 M Addison's disease 0.6 1.1 0.5 1.7 2.5
a.H. 39 M Addison's disease 1.5 1.5 1.4 2. I 5.3
/
.-.-\ j'
e-_e__e
E
-; 10
c:
r
\!l
r
t
S glucagon 1mg sc
Q> regular insulin 009U/kg IV
t: lO0rl
:x .
o , ----%,80:~/~~~ 60f, , ~~
ror
o 0 30 60 90 120 150 180 210 mIn.
Fig. 7. Serial plasma HGH and blood glucose values
before and after receiving a concomitant iv injection of
regular insulin (0.09 U/kg) with sc injection of one mg
glucagon.
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CONCENTRATIONS AFTER SC GLUCAGON.
(ng/m1) Blood glucose (mg/100m1)
150 180 0 30 60 90 120 150 180
min min min min min min min min min
22.6 17.3 96 142 123 92 84 89 88
4.8 4.1 1.8 3.1 5.2 3.4 2.3 2.1 3.0
27.4 23.3 97 149 120 90 82 89 89
6.8 5.5 2.6 2.6 8.3 4.4 2.0 3.3 4.1
19.4 7.8 94 133 127 95 87 89 87
5. 7 3.0 2.3 4.3 5.8 5.6 4. 7 2.8 4.6
1.5 1.2 92 129 121 97 78 76 78
0.2 0.1 4.5 9.6 13.4 8.0 4.2 4.5 4.8
18.1 9.9 145 207 223 222 194 168 144
3.1 3.5 6.4 13.6 14.2 22.1 22.3 17.5 15.8
32.0 29.5 120 175 190 167 128 105 91
9.3 9.4 3. 7 2.4 8.7 14.1 13. 7 8.5 3.8
A PATIENT ADRENALECTOMIZED BILA TERALLY AND IN 2 PATIENTS WITH ADDISON'S DISEASE.
(ng/m1) Blood glucose (mg/100 mIl
150 180 0 30 60 90 120 150 180
min min min min min min min min min
26.0 22.5 84 148 114 92 76 70 68
18.0 17.0 114 144 156 130 98 80 82
28. 7 16.2 86 136 130 104 76 56 64
DISCUSSION
Recently, many stimulation tests have been used to assess the HGH
reserve. Some of these tests include insulin, lysine vasopressin, pyrogen and
glucagon administration.
The stimulatory effect of hypoglycemia upon HGH secretion has been
demonstrated many times (7-9) since its first description by ROTH et ale in
1963 (1). It has been cited tha.t the magnitude of fall in blood glucose was
50% or more of the fasting level, which was the criterion as being sufficient
to provoke adequate HGH elevation (1, 8, 10-11). On the other h~nd, ROTH
et ale (12) have demonstrated that a rapid fall in blood glucose, 'Yithout
attaining hypoglycemia, could induce a significant rise in HGH, and Ko~ et ale
(13) and GLICK (14) found that the threshold fall of blood glucose to ~elease
HGH was between 20 and 30 mg/IOO ml. LUFT and CERASI (15) reported that
a decrease in blood glucose of at least 10 mg/l 00 ml was almost always accom-
pa.nied by a substantial rise in plasma HGH and that the magnitude of rise in
HGH was followed by the degree of hypoglycemia obtained. The present
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data indicate that the decline of blood glucose level is more significant factor
than the absolute level of glucose itself with respect to the release of HGH,
i. e. the HGH response is related to the per cent blood glucose decrement
rather than to the absolute minimal blood glucose levels (Figs. 1 & 2). And
then, it was also revealed that the magnitude of fall in blood glucose which
was the criterion as being sufficient to provoke HGH secretion for clinical
evaluation was 28.6% or more of the fasting level.
Because of the great variation in the normal response of plasma HGH to
insulin hypoglycemia, it is difficult to determine a borderline between normal
and subnormal responses. The present results obtained from 40 insulin tests
performed on normal subjects demonstrate that 9.4 ng/ml or higher HGH
increment was recognized normal, being in close agreement with GREENWOOD
et al. (16) and PARKER et at. (17). Although a defective HGH response to
insulin test has been reported in patients with acromegaly (18), some patients
in this study showed a rise in plasma HGH while others failed to do so, in
agreement with observations made by ROTH et al. (19), GLICK et al. (9) and
GREENWOOD et al. (20). In patients with hypothalamo·pituitary disease, as
noted by RABKIN and FRANTZ (21) and KAPLAN et at. (22), unresponsiveness was
associated with a complete lack of HGH elevation in response to insulin
hypoglycemia. The lack of HGH response in the postoperative hypothalamo-
pituitary tumor group may indicate that the integrity of neural or vascular
connections between the hypothalamus and the pituitary appears to be neces-
sary for responsiveness of HGH secretion to the change in blood glucose.
Although conflicting results have been reported on plasma HGH response to
insulin-induced hypoglycemia in hyperthyroidism (23-25), it has been generally
accepted that patients with hypothyroidism exhibit impaired release of HGH
following insulin-induced hypoglycemia (26, 27). The insulin-induced hypo-
glycemia was less effective stimulus to HGH secretion in patients with
Cushing's syndrome than in normal subjects, agreeing with the well known
facts that administration of glucocorticoids supresses the HGH response to
hypoglycemia (8, 28). The diagnostic value of insulin test outweighs its
possible risk. No patients in the present studies have experienced severe side
effects; only one complication encountered in present 131 studies was arrhy-
thmia, which responded promptly to the intravenous administra.tion of glucose.
Although vasopressin has been reported to cause a reliable increase in
plasma HGH in monkeys as well as men (29-32), CZARNY et al. (33), BROSTOFF
et al. (34) and KARP et al. (35) have reported that LVP caused an increase in
plasma corticosteroid levels wherea.s plasma HGH response to LVP was vari-
able. The present results indicate that an increase in plasma HGH is seldom
seen after LVP, and the response in normal subjects is not consistent enough
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to be a reliable test for HGH reserve despite the side-effects such as vasocon-
striction and abdominal colic. Although it has been reported that bacterial
pyrogen stimulated both cortisol and HGH release (36, 37), the present results
reveal that HGH levels rise beyond the normal threshold (9. 4 ng/ml) in only
five of 16 control subjects tested. Since LVP and pyrogen produce varying
degrees of side-effects and they are less specific and unpredictable in the
release of HGH, they may be limited in their widespread use for HGH stimu-
lation tests. On the other hand, insulin-induced hypoglycemia generally
gave rise to higher HGH levels, and pattern of response was more consistent
than those seen in LVP and pyrogen tests. Therefore, insulin-induced hypo-
glycemia is the better stimulus for routine testing of HGH reserve than LVP
and pyrogen.
HGH secretion in response to sc injection of glncagon is generally
accepted in recent years (3-5), although some have reported no significant
HGH response to iv glucagon (2, 38). CAIN et at. (5) demonstrated that one mg
glucagon administered either sc in a single dose, or in infusion over 30 min
gives consistent and reproducible HGH rises, as compared with a single bolus
of glucagon. In the present study, one mg glucagon was administered sc to
all subjects except in dose response study. In all the normal subjects, HGH
secretion was observed in response to sc injection of glucagon, and no false
negative response as descibed by MITCHELL et at. (39) was noted. In patients
with insufficiency of HGH secretion as shown by orher tests, no HGH re-
sponse was observable in glucagon test.
The exact mechanism by which glucagon causes HGH release is obscure.
While it is conceivable that difference between the sc and iv glucagon admi-
nistrations is due to a long latent period for its effect, this seems unlikely in
view of the short circulating half-life (about 10 min) of glucagon in serum
(40, 41), and its rapid stimulation of insulin release and glycogenolysis (42).
HGH secretion in response to glucagon, unlike the stimulation by other sub-
stances, is characterized by a long interval from glucagon loading to HGH
secretion. This might suggest that glucagon stimulates the HGH secretion via
some intermediate substances or metabolic changes, but no sufficient data are
available for confirmation. Some investigators suggest a possibility that HGH
secretion in response to sc glucagon is related to the fall in blood glucose
from the previously elevated level, rather than a specific response to glucagon
(43, 44). This possibility is denied by the following observations: (A) In
some studies of HGH release in which the rise and fall in glucose concentra-
tion were induced by glucose instead of glucagon, a substantial number of
adult subjects showed no increase in HGH (45, 46). (B) In a few normal
subjects, both blood glucose and HGH concentrations reached a peak almost
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the same time (39, 47). (C) The glucagon·induced rise in plasma HGH failed
to be prevented by the coadministration of insulin (Fig. 7). (D) In patients
with diabetes mellitus, HGH secretion in response to sc glucagon is similar to
that in normal subjects despite persisting hyperglycemia (Table 3). (E)
Despite marked hyperglycemia lasting for a long period of time after dexa-
methasone administration, the timing of response and the magnitude of HGH
are similar to those in the untreated group (Table 3). Then, it is unlikely
that the rise and subsequent fall of glucose are the sole mechanism responsible
for the effect of glucagon on HGH secretion. Such non-participation of blood
glucose might indicate that glucagon will be a potentially useful tool in
evaluating pituitary HGH reserve in patients with diabetes mellitus.
It has been reported that adrenomedullary secretion was stimulated by
glucagon (48-51), and recently glucagon has been used for the provocation
test in pheochromocytoma (51). On the other hand, in view of the reports on
the invasion of catecholamine in to the hypothalamus (52, 53), it may be
possible that HGH secretion in response to sc glucagon is triggered by cate-
cholamine via the stimulation of adrenal medulla, although it has been
reported that the administration of epinephrine to normal subjects was not
followed by elevation of plasma HGH (1). Such a possibility can be denied,
since glucagon-induced HGH secretion was observed in a subject adrenalecto-
mized bilaterally and in two patients with Addison's disease (Table 4).
DANFORTII et al. (38) have described that a rise in the plasma HGH after gluca-
gon is the result of nonspecific stress. However, other stresses such as veni-
puncture or surgery do not necessarily cause a consistent rise in plasma HGH
(54, 55), and the fact that in most instances there was no change in HGH
levels for 90 min after administration of glucagon seems to almost deny the
stress playing a role in elevating HGH levels. The mechanism of glucagon-
induced HGH secretion is being further investigated. Glucagon will gain
popularity in clinical practice because of its ease of administration and its
consistent action of HGH release.
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